[go: up one dir, main page]

MX9704372A - Tratamiento de carcinoma. - Google Patents

Tratamiento de carcinoma.

Info

Publication number
MX9704372A
MX9704372A MX9704372A MX9704372A MX9704372A MX 9704372 A MX9704372 A MX 9704372A MX 9704372 A MX9704372 A MX 9704372A MX 9704372 A MX9704372 A MX 9704372A MX 9704372 A MX9704372 A MX 9704372A
Authority
MX
Mexico
Prior art keywords
carcinoma treatment
treatment
carcinoma
carcinomas
inducer
Prior art date
Application number
MX9704372A
Other languages
English (en)
Inventor
Lawrence Sterling Young
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham filed Critical Univ Birmingham
Publication of MX9704372A publication Critical patent/MX9704372A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Para el tratamiento de carcinomas en células epiteliales y para la prevencion de proliferacion de células epiteliales se usa un enlazador de receptor de CD40; el CD40 se puede usar junto con por lo menos un agente antineoplásico y/o inductor de CD40.
MX9704372A 1994-12-13 1995-12-01 Tratamiento de carcinoma. MX9704372A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425060.2A GB9425060D0 (en) 1994-12-13 1994-12-13 Carcinoma treatment
PCT/GB1995/002807 WO1996018413A1 (en) 1994-12-13 1995-12-01 Carcinoma treatment

Publications (1)

Publication Number Publication Date
MX9704372A true MX9704372A (es) 1998-02-28

Family

ID=10765814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9704372A MX9704372A (es) 1994-12-13 1995-12-01 Tratamiento de carcinoma.

Country Status (12)

Country Link
EP (1) EP0806963B1 (es)
JP (1) JP4076230B2 (es)
AT (1) ATE203676T1 (es)
AU (1) AU691996B2 (es)
CA (1) CA2207779C (es)
DE (1) DE69522012T2 (es)
FI (1) FI118918B (es)
GB (1) GB9425060D0 (es)
MX (1) MX9704372A (es)
NO (1) NO318587B1 (es)
NZ (1) NZ296161A (es)
WO (1) WO1996018413A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0751781T3 (da) * 1993-12-23 2004-08-09 Immunex Corp Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP1946775A3 (en) * 1998-08-11 2008-08-06 Biogen Idec Inc. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7138379B2 (en) * 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005044305A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
EP1885399B1 (en) 2005-05-26 2010-10-20 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
US8926979B2 (en) 2005-11-01 2015-01-06 Novartis Ag Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
ES2444465T5 (es) 2005-12-09 2023-11-30 Academisch Medisch Centrum Bij De Univ Van Amsterdam Medios y procedimientos para influenciar la estabilidad de las células productoras de anticuerpos
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
CA2704499C (en) 2007-11-07 2020-03-10 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
CN102459639A (zh) 2009-04-18 2012-05-16 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法
WO2011008093A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
NZ611600A (en) 2010-12-02 2015-02-27 Aimm Therapeutics Bv Means and methods for producing high affinity antibodies
US8778345B2 (en) 2011-04-29 2014-07-15 Apexigen, Inc. Anti-CD40 antibodies
WO2014070934A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
AU2015211480B2 (en) 2014-01-31 2020-05-14 Kling Biotherapeutics B.V. Means and methods for producing stable antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
WO1996018413A1 (en) 1996-06-20
NO972732D0 (no) 1997-06-13
JP4076230B2 (ja) 2008-04-16
EP0806963A1 (en) 1997-11-19
CA2207779A1 (en) 1996-06-20
ATE203676T1 (de) 2001-08-15
FI118918B (fi) 2008-05-15
CA2207779C (en) 2009-10-06
FI972484A0 (fi) 1997-06-12
GB9425060D0 (en) 1995-02-08
NO972732L (no) 1997-06-13
AU3988495A (en) 1996-07-03
DE69522012T2 (de) 2002-04-25
AU691996B2 (en) 1998-05-28
FI972484L (fi) 1997-06-12
NZ296161A (en) 2001-10-26
EP0806963B1 (en) 2001-08-01
DE69522012D1 (de) 2001-09-06
NO318587B1 (no) 2005-04-11
JPH10510526A (ja) 1998-10-13

Similar Documents

Publication Publication Date Title
GB9425060D0 (en) Carcinoma treatment
MXPA02001726A (es) Celda de combustible y placa bipolar para utilizarse con la misma.
GR3017460T3 (en) Direct compression cholestyramine tablet and solvent-free coating therefor.
AU5835098A (en) Use of pyrimidine derivatives for the prevention of cancer, on their own or in combination with other therapeutic measures
TR200000726T2 (tr) Budesonid ve formoterol'ün yeni kullanımı.
DK0877734T3 (da) Quinolin- og quinazolinforbindelser, der er egnede i terapi
EP0290455A4 (en) HALOARYLNITRILE DEGREASING GENE, THE USE THEREOF AND THE CELLS THAT CONTAIN IT.
ES292314U (es) Un articulo sanitario
EP0631134A3 (en) Platform for electrophoresis and plate.
EP0162017A3 (en) Homo and copolymer, materials coated therewith and its use
TW355847B (en) A surface treatment steel plate used for battery case, batterycase and battery using the case
HRP930344B1 (en) New retinoides
ZA866568B (en) Soluble,crosslinkable acrylate copolymer,processes for its preparation,and coating agents based on the acrylate copolymer
DE59004277D1 (de) Copolymerisat sowie dessen Verwendung.
MX9700813A (es) Nuevos derivados 3-substituidos de 3h-2,3-benzodiazepina, su preparacion y su uso como medicamentos.
ZA972776B (en) 4-[(thien-2-yl)methyl]-imidazole analgesics
ES2013025A6 (es) Un metodo para preparar 24r-escimnol.
EP0066389A3 (en) Thermal stabilization of acrylonitrile copolymer fibers
ES8504419A1 (es) Procedimiento para la sensibilizacion al calor de dispersiones acuosas de polimero.
EP1032266A4 (en) USE OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION IN THE TREATMENT OF ARTHRITIS
ZA938799B (en) Novel heterocyclic compounds with anti-asthmatic/anti-allergic, anti-inflammatory, positive inotropic and blood pressure-reducing effect.
AU6985194A (en) Soluble, conductive copolymer, the preparation and use thereof
EP0373658A3 (en) Use of quinoline derivatives in treating cancer
AU8136398A (en) Sheet aligning device and sheet treating device provided with the same
Bieniecki THE IMPULSE POWERS SOURCE IN CATHODIC PROTECTION INSTALLATIONS(Polish)

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees